Berobenatide + MET233i
Pfizer / Metsera
Long-acting GLP-1 plus amylin/calcitonin activity.
Results availability
No numerical study results are currently summarized for this profile. The development stage and linked studies are listed below.
Mechanism at a glance
Obesity stage by formulation
Latest: Pfizer lists the GLP-1/amylin combination in Phase 2 obesity development.
Next: Combination efficacy and tolerability data.
Clinical study records
Obesity and weight-management studies appear first. Related-condition trials follow by phase, with focus labels to show what each study evaluates. Study stage and results reporting are listed separately. Results summarized above are identified as peer-reviewed or sponsor reported. Otherwise, the label states whether results were posted to a registry or reported in the linked source.
Obesity and weight-management studies
Phase 2 studies1 record
SOLIS-1
Combination weight managementAdults with overweight or obesity; evaluates long-acting PF-08653945 (PF’3945) alone and in combination with berobenatide, including weekly/monthly regimens.
